COMP <GO>
XERS vs PGEN // DIVIDEND YIELD & FCF PAYOUT SAFETY
Xeris Biopharma Holdings Inc. (NASDAQ) VS. Precigen Inc. (NASDAQ) • 15-METRIC TALLY: XERS 7
— PGEN 1
■ METRIC PARITY
LAST: $10.35 (+1.77%) • MKT CAP: $1.85B
dividend-safety
0.00%
LAST: $5.25 (+2.14%) • MKT CAP: $1.84B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XERS VS. PGEN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XERS | PGEN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.00% | -35.00% | +51.00 | XERS | /roic <GO> |
| EV/EBITDA & P/E Valuation | 83.1x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 1.46% | -3.78% | +5.24 | XERS | /fcf-yield <GO> |
| Operating Margin | 8.50% | -60.00% | +68.50 | XERS | /operating-margins <GO> |
| Net Profit Margin | 0.20% | -60.00% | +60.20 | XERS | /net-margins <GO> |
| Revenue Growth (YoY) | 43.70% | 146.70% | -103.00 | PGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.11 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 3/9 | +4.00 | XERS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 32.6 | +17.20 | XERS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.85B | $1.84B | $13.9M | XERS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XERS REV | PGEN REV | XERS GROSS % | PGEN GROSS % | XERS FCF | PGEN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $291.8M | $9.7M | — | — | $28.6M | -$89.8M |
| FY 2024 | $203.1M | $3.9M | — | — | -$37.0M | -$76.8M |
| FY 2023 | $163.9M | $6.2M | — | — | -$47.0M | -$66.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XERS // BETA —
PGEN // BETA —